

October 31, 2025

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

**Sub: Press Release on Un-audited Financial Results (Standalone and Consolidated)
for the Quarter and Half Year ended September 30, 2025**

Dear Sir/ Madam,

Please find enclosed herewith the Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2025.

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay Gujral
Company Secretary & Compliance Officer

Encl.: As above

Dr Lal PathLabs Limited records revenue of Rs 731 Cr in Q2 FY 2025-26

New Delhi, India, October 31, 2025 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended September 30, 2025.

Consolidated Performance Highlights: Q2 FY26 vs Q2 FY25

- Revenue increased by 10.7% in Q2 FY26 and FH26 by 11.0%
- EBITDA increased by 10.8% with a margin of 30.7%
- PAT increased by 16.4% with a margin for of 20.8%
- Interim Dividend of Rs. 7 per share for Q2 FY26
- Board has approved bonus issue in the ratio of 1:1 i.e. 1 Bonus share for every 1 share held on record date

Financial Overview (Consolidated) in Rs Cr

Particulars	Q2			FH		
	FY26	FY25	Gr %	FY26	FY25	Gr %
Revenue	731	660	10.7%	1400	1262	11.0%
Material consumed	142	127		271	247	
Employee benefit Expenses	132	124		264	241	
Fees to collection centres	106	94		198	177	
Other Expenses	126	113		250	225	
EBITDA	224	202	10.8%	416	372	11.8%
<i>Margins</i>	<i>30.7%</i>	<i>30.7%</i>		<i>29.7%</i>	<i>29.5%</i>	
Other Income	25	22		53	42	
Depreciation Cost	41	35		75	70	
Finance Cost	5	6		9	12	
PBT	204	183	11.2%	385	333	15.5%
<i>Margins</i>	<i>27.9%</i>	<i>27.7%</i>		<i>27.5%</i>	<i>26.4%</i>	
PAT	152	131	16.4%	286	239	20.0%
<i>Margins</i>	<i>20.8%</i>	<i>19.8%</i>		<i>20.4%</i>	<i>18.9%</i>	
EPS	18.1	15.5	16.2%	33.9	28.3	19.9%



About Dr Lal PathLabs Limited

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2025 the company has 298 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 6,607 Patient Service Centers (PSCs) and 12,365 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel
Group Chief Financial Officer
Dr Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Kritika Khatwani
Adfactors PR

+91 8604801332
kritika.khatwani@adfactorspr.com

For further information on Dr Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.